Nanobiotix Shares Drop Nearly 4% Yet Still Show Remarkable Yearly Growth
The French biotech company experiences another challenging session at the start of the month. Its stock marks a significant decline while the Paris market trends upwards. The digestion phase following the mid-May record high continues.
Nanobiotix Falls by 3.47%, Among the Sharpest Declines in the SBF 120
Nanobiotix shares drop 3.47% to €32.86, while the SBF 120 gains 0.30% and the CAC 40 increases by 0.36%. The stock is among the largest declines in the broad index, alongside the day's penalized tech stocks. This retreat is part of a short-term negative trend: the biotech has lost nearly 10% over the week, extending the consolidation phase that began after the historic peak on May 18 at €47.66. However, the annual performance remains exceptional, at nearly 795% over twelve months, and the rise still reaches more than 27% over three months. Comparable health sector stocks show mixed results, with Sanofi down 0.27% and Eurofins Scientific dropping 0.58%.
Stock Price Falls Below its 20-Day Moving Average but Remains Well Above its 200-Day Long Average
The stock significantly falls below its 20-day moving average, located at €37.11, marking a gap of 11.45%, indicating that the short-term momentum has reversed. However, it maintains a comfortable cushion above its 200-day moving average at €20.96, over 56% above this long-term benchmark, illustrating the extent of the rally over the past year. The RSI at 48 indicates a neutral setup, with no signs of exhaustion or overbuying. The technical support identified at €26.34 remains far from the current price, while the resistance at €46.18 corresponds to the area of recent historic highs. As a reminder, the May sequence was marked by a global offering of shares and an upgraded price target by Jefferies to €60. The next calendar step remains the technical digestion between the recently surpassed 50-day moving average at €31.15 and the now out-of-reach 20-day moving average.
